Skip to main content

Table 1 Characteristics of eligible clinical trials (N=406)

From: Definitions and elements of endpoints in phase III randomized trials for the treatment of COVID-19: a cross-sectional analysis of trials registered in ClinicalTrials.gov

  Severe (N=108) Non-severe (N=298)
Regiona
 Single region 68 (63.0%) 226 (75.8%)
 Multi-region 21 (19.4%) 23 (7.7%)
 Unknown 19 (17.6%) 49 (16.4%)
Countriesa
 Canada 4 (3.7%) 19 (6.4%)
 USA 35 (32.4%) 58 (19.5%)
 France 10 (9.3%) 31 (10.4%)
 Germany 8 (7.4%) 9 (3.0%)
 Italy 5 (4.6%) 16 (5.4%)
 Russia 9 (8.3%) 11 (3.7%)
 Spain 11 (10.2%) 18 (6.0%)
 UK 11 (10.2%) 13 (4.4%)
 China 3 (2.8%) 9 (3.0%)
 Japan 6 (5.6%) 6 (2.0%)
 Brazil 14 (13.0%) 22 (7.4%)
 Others 40 (37.0%) 124 (41.6%)
Number of endpoints
 Mean (SD) 12.8 (10.7) 9.0 (7.7)
 Median (IQR) 9 (6, 16.3) 7 (4, 12)
Number of primary endpointsa
 1 86 (79.6%) 216 (72.5%)
 2 13 (12.0%) 42 (14.1%)
 ≥3 9 (8.3%) 40 (13.4%)
Number of armsa
 1b 18 (16.7%) 63 (21.1%)
 2b 64 (59.3%) 177 (59.4%)
 ≥3b 26 (24.1%) 58 (19.5%)
Sample size (trials with 1 armb)
 Mean (SD) 367.8 (378.2) 396.3 (553.2)
 Median (IQR) 205 (100, 462) 200 (100, 466)
Sample size (trials with 2 armsb)
 Mean (SD) 519.2 (652.9) 576.9 (831.3)
 Median (IQR) 372 (230, 600) 300 (108, 690)
Sample size (trials with ≥3 armsb)
 Mean (SD) 806.6 (787.3) 1149.1 (2433.9)
 Median (IQR) 475 (200, 1116) 305 (200, 700)
  1. aFrequency (percentage); bA single drug with multiple doses that was placed under the same “Arm” in interventions was considered as one arm
  2. SD standard deviation, IQR interquartile range